trendlines

Investing to improve the human condition.
Food and Health

Steve Rhodes
Chair

Todd Dollinger
Chair

Haim Brosh
CEO

November 2023



Legal disclaimer.

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Agenda.

- Management changes
- Israel Update
- SIAS Award
- Letter of Intent
- Singapore medtech companies
- Spotlight on a few outstanding portfolio companies
- Q&A

The management change story.

- Board considerations
- Appointment of Haim
- Steve and Todd’s continuing role
- Focus on portfolio companies
  - Raises
  - Exits

Congratulations to Haim Brosh.



Haim brings more than 20 years of experience in senior- and executive-level accounting and management positions at public and private companies. He holds a degree in in accounting and economics from Tel Aviv University and is a Certified Public Accountant in the State of Israel. Haim joined Trendlines in 2014 and was named Chief Financial Officer in 2018.

Israel Update.

- Resilience of the country and the start-up sector
- Our response as a company
  - commitment to the **community**
  - commitment to our **employees**
  - commitment to our **companies**
  - commitment to our **shareholders**





Letter of Intent.

- Trendlines received a non-binding Letter of Intent ("**LOI**") for the acquisition of a portfolio company.
- Estimated share of the sale proceeds for Trendlines in cash is approximately S$8 million (US$6 million)*.

* At $1.35 SGD to USD

SIAS Investors' Choice Awards 2023.


Trendlines was awarded the Most Transparent Company Award for its outstanding efforts in **Transparency and Disclosure** practices. The SIAS Awards Ceremony was held on 8 November 2023.



Singapore medtech companies' progress.

- ✓ Three companies completed Series A round







- ✓ Three companies closing SAFE rounds







Spotlight on a few Outstanding Portfolio Companies.




AI-based platform for full crop monitoring.

AgroScout collects and integrates data from multiple sources (field, air, space) and scientifically analyzes them to produce detection and recognition reports that supply actionable insights of agribio risks and sustainability monitoring.

Achievements

- 2022: launched global sales, with leading partners such as PepsiCo
- Partnering with global players: Kraft Heinze, Mondelez, Adama, Pepsico, DJI, AECI
- Providing service on multiple crops

AgroScout
Detection Done Right



AgroScout's first target is the potato market, the 4th most important crop globally

Founded 2017

CEO
Simcha Shore

IP Provisional patent submitted

Funding US$11.3 million, including grants

Our board member
Sarai Kemp, Steve Rhodes

Consensus Business Group

Kibbutz Yiron

Kibbutz Yotvata

רשות החדשנות
Israel Innovation Authority

trendlines


Advanced robotic system for greenhouses.

Greenhouse Robotic Worker (GRoW) is a platform for harvesting greenhouse crops and analyzing data for yield estimation and stress detection, with the purpose of reducing reliance on manual labor.

Achievements

- Launched sales in Europe and China
- Strategic partnership established with a major Dutch player in high-tech greenhouses
- Beta testing in commercial greenhouse in Holland
- Grant funding received from European Union

METOMOTION



MetoMotion's first target is a robotic harvester for greenhouse tomatoes

Founded 2016

CEO
Adi Nir

IP

Funding US$7 million, including grants

Our board members
Steve Rhodes

European Innovation Council

RIDDER

רשות החדשנות
Israel Innovation Authority

trendlines

The natural food-color revolution.

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and the food industry.

Achievements

- Full POC: color production and application in food products
- Commercial agreement with DSM
- Successful pilots with industry leaders, including Nestlé
- R&D collaboration agreement with Ginkgo Bioworks

Financial

- Last investment round: US$14.5 million

Phytolon



Plant-based colors produced via cost-effective and sustainable fermentation of yeast

Founded 2018;
23 employees;
Yokne'am Illit, Israel

Co-Founders
Halim Jubran, PhD, CEO
Tal Zeltzer, PhD, CTO

IP Licensed from Weizmann Institute of Science

Funding US$20.7 million, including grants

Our board members
Nitza Kardish, Barak Singer

ARKIN HOLDINGS · CIBUS · Consensus Business Group · DSM · eit Food · GINKGO BIOWORKS · millennium foodtech · רשות החדשנות Israel Innovation Authority · trendlines

Meniscus repair system.

All-suture, knotless meniscus repair system.

Achievements

- Initial sales
- FDA and CE approvals; ISO13845:2016 certified
- US distribution in place; distributors in Colombia, Chile, Ecuador, Panama, Guatemala, Venezuela, Taiwan, Israel, and New Zealand
- **Phil Davidson, MD,** appointed Medical Director and Chair of SAB; **Ken Zaslav, MD,** joins SAB
- Chair **Robert Bash**

Arcuro Medical



The all-suture, knotless meniscus repair system developed by Arcuro

Founded 2013

CEO
Lee Ranon

IP Patents in US, China, Europe, Israel

Funding US$10.7 million, including grants

Our Board Members
Todd Dollinger
Barak Singer

Consensus Business Group Distributors Physicians Private Strategics רשות החדשנות Israel Innovation Authority trendlines

Catheter for treating ischemic stroke.

Next-generation aspiration catheter for treating ischemic stroke.

Achievements

- Tested at the New England Center for Stroke Research and the Jacobs Institute, Buffalo, NY
- Key opinion leaders (KOLs) validated concept
- KOL **Prof. Raul Nogueira** joined the advisory board
- Chair **Amir Belson, MD (serial entrepreneur)**
- FIH clinical trial underway with positive results

ceretrieve



Aspiration catheter for improved handling, enhanced clot aspiration, better retention

Initiated 2016

CEO
Maysa Mustafa

IP Filed 2 National phase

Funding US$7.3 million, including grants

Our Board Member
Barak Singer

Consensus Business Group | רשות החדשנות Israel Innovation Authority | trendlines

Nonsurgical prolapse repair device.

Minimally invasive, nonsurgical, incision-free and mesh-free repair device to treat pelvic organ prolapse (POP) in the ambulatory or office-based settings.

Achievements

- Received FDA clearance
- Successful completion of 1 year follow-up on the FIW clinical study
- First cases performed in the US with excellent feedback from KOLs
- Leading US physician founders
- Animal/cadaver study results published in The Journal of Minimally Invasive Gynecology
- Won €5.5 million in funding from the prestigious EU EIC program
- Chair: **Robert Auerbach, MD** (former President, Cooper Surgical)

escala medical



Incision/mesh-free repair option for women with mild to moderate POP

Founded 2014

CEO
Edit Goldberg

IP Granted US patent, 2 National phase

Funding US$9 million, including grants

Our Board Members
Todd Dollinger
Barak Singer

Consensus Business Group

European Innovation Council

רשות החדשנות Israel Innovation Authority

trendlines

Endoscopic ultrasound biopsy system.

Next-generation endoscopic ultrasound-guided biopsy device for precision medicine, for improved diagnosis of the gastrointestinal system and adjacent organ tumors.

Achievements

- Received FDA
- Ongoing FIH clinical
- Licensing deal with HekkaBio for the Japanese market
- Trendlines Innovation Labs and Rambam Hospital invention
- Active Director **Carl Rickenbaugh** (ex CR Bard)

LIMACA MEDICAL



The Limaca device retrieves core tissue samples with fewer stabs

Founded 2017

CEO
Assaf Klein

IP National phase

Funding US$5.5 million, including grants

Our Board Members
Todd Dollinger
Barak Singer

bus. dev. stage


HekaBio Miracles through Partnership

רשות החדשנות Israel Innovation Authority

Consensus Business Group

trendlines

Q&A.







trendlines

Investing to improve the human condition.

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com

November 2023

Steve Rhodes, Chair
steve@trendlines.com

Todd Dollinger, Chair
todd@trendlines.com

Haim Brosh, CEO
haim@trendlines.com